Internal Medicine

Incidence of myopia was 7.9% higher in the exposure group, compared to the non-exposure group from grade 2 to grade 3.

The approval of ranibizumab-nuna marks the first ophthalmology biosimilar to become FDA approved in the United States.

Though well-tolerated and highly efficacious, the biologic was linked several adverse events in pediatric patients with atopic dermatitis including facial erythema and herpes simplex virus.

In this episode of Derm Discussions, vitiligo expert John Harris, MD, PhD, discusses new tactics and therapeutic options in treating inflammatory skin disorders like vitiligo, alopecia areata, and atopic dermatitis.

The evidence regarding patients with entecavir-treated chronic hepatitis B without maintaining virological response is limited and uncertain.

Dr. Papadopoulos reports on new phase 3 data from the LIBERTY VOYAGE ASTHMA study on patients aged 6-11 with moderate-to-severe asthma.

Dr. Ezhkova and fellow investigators found that low UV exposure prompted an increase in pigmentation production through melanocytes in the body.

The new PDUFA date for Nefecon will be December 15, 2021.

Kim Smith-Whitley, MD, discussed her research on voxelotor as treatment for children with sickle cell disease.

A 12-week trial assessing the effects of a low calorie, low carbohydrate diet facilitated by community pharmacists suggests this approach could contribute to the remission of type 2 diabetes in adult patients.

Dr. Javed Butler referenced several promising ongoing trials of diabetes-related medications and their effects on heart disease but added that unclear guidelines kept them from being properly acknowledged.

Though select diabetes guidelines suggest the use of continuous glucose monitoring on patients with diabetic patients on intensive therapy, the potential benefits on type 2 patients without insulin and pre-diabetes patients has yet to be fully explored.

While some treatments did not result in reduced instances of strokes in patients, others such as GLP-1 agonists provided Dr. Inzucchi with new opportunities for cardiovascular disease prevention.

Dr. Donna H. Ryan presents data on emerging pharmacological strategies that could aid patients in achieving optimal weight loss and prevent risk of cardiovascular events and diabetes.

Despite having lower burden of several cardiovasculard disease risk factors, cardiovascular mortality is higher in African Americans, which Dr. Dagogo-Jack attributes to disparities in patient care.

Dr. Peter Grant admits that the phenotypes surrounding certain cardiovascular diseases are complex, but notes treatments can be recommended based on individual patients’ complications.

Dr. Chovatiya speaks on the advancements made in vitiligo research, how the disease can disproportionately impact patients of different ethnicities, and how each patient can be properly treated.

In an interview with HCPLive, Dr. Jean-Pierre Llanos-Ackert and Dr. Bill Cook discuss how tezepelumab resulted in improved lung function and an 86% reduction in exacerbation rates in this patient population.

Data show no patients in the study (n = 510) had BCVA worse than 0.3 (log MAR 0.48) due to diabetic retinopathy.

Serum concentrations of aminotransferases improved for HCC-DAA and DAA-HCC groups 1 year following surgery.

A rarity in biologic treatments for patients with moderate-to-severe plaque psoriasis, Dr. Miller notes that patients treated with guselkumab recorded overwhelmingly positive PASI scores.

As with previous studies, the investigators found that the biologic aided in reducing severe exacerbations and improving lung function in patients with evidence type 2 inflammation.

Investigators believe the current climate crisis can lead to an increased risk of COPD exacerbations and mortality rates, both of which have been noted in prior research.

More research is needed on the safety and efficacy of multiple biologics.

New data describes risk factors associated with increased prevalence of sexual dysfunction among patients with type 1 and type 2 diabetes.

The US Food and Drug Association are also requiring new and updated warnings for baricitinib and upadacitinib, 2 other arthritis medicines in the same drug class as tofacitinib.

Six-month paliperidone palmitate is the only twice-yearly injectable treatment for patients with schizophrenia.

Investigators found no significant differences in the efficacy and safety of the originator or biosimilars in children with juvenile idiopathic arthritis.

Ketamine was not superior to morphine in reducing pain scores.

Recent phase 3 trial data confirms that dupilumab is the first biologic medicine is the first to reduce severity and symptoms of atopic dermatitis in pediatric patients.